324 related articles for article (PubMed ID: 16282321)
1. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.
Oddo S; Caccamo A; Tran L; Lambert MP; Glabe CG; Klein WL; LaFerla FM
J Biol Chem; 2006 Jan; 281(3):1599-604. PubMed ID: 16282321
[TBL] [Abstract][Full Text] [Related]
2. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
3. Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex.
Welikovitch LA; Do Carmo S; Maglóczky Z; Szocsics P; Lőke J; Freund T; Cuello AC
Acta Neuropathol; 2018 Dec; 136(6):901-917. PubMed ID: 30362029
[TBL] [Abstract][Full Text] [Related]
4. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
5. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
6. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
7. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
[TBL] [Abstract][Full Text] [Related]
8. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.
Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP
J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470
[TBL] [Abstract][Full Text] [Related]
9. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
[TBL] [Abstract][Full Text] [Related]
10. Soluble aβ promotes wild-type tau pathology in vivo.
Chabrier MA; Blurton-Jones M; Agazaryan AA; Nerhus JL; Martinez-Coria H; LaFerla FM
J Neurosci; 2012 Nov; 32(48):17345-50. PubMed ID: 23197725
[TBL] [Abstract][Full Text] [Related]
11. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
Hirata-Fukae C; Li HF; Hoe HS; Gray AJ; Minami SS; Hamada K; Niikura T; Hua F; Tsukagoshi-Nagai H; Horikoshi-Sakuraba Y; Mughal M; Rebeck GW; LaFerla FM; Mattson MP; Iwata N; Saido TC; Klein WL; Duff KE; Aisen PS; Matsuoka Y
Brain Res; 2008 Jun; 1216():92-103. PubMed ID: 18486110
[TBL] [Abstract][Full Text] [Related]
12. Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice.
Rasool S; Martinez-Coria H; Milton S; Glabe CG
Mol Neurobiol; 2013 Dec; 48(3):931-40. PubMed ID: 23771815
[TBL] [Abstract][Full Text] [Related]
13. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
[TBL] [Abstract][Full Text] [Related]
14. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology.
Lopes JP; Blurton-Jones M; Yamasaki TR; Agostinho P; LaFerla FM
J Alzheimers Dis; 2009; 16(3):541-9. PubMed ID: 19276549
[TBL] [Abstract][Full Text] [Related]
15. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.
Tomiyama T; Matsuyama S; Iso H; Umeda T; Takuma H; Ohnishi K; Ishibashi K; Teraoka R; Sakama N; Yamashita T; Nishitsuji K; Ito K; Shimada H; Lambert MP; Klein WL; Mori H
J Neurosci; 2010 Apr; 30(14):4845-56. PubMed ID: 20371804
[TBL] [Abstract][Full Text] [Related]
16. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
[TBL] [Abstract][Full Text] [Related]
17. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
Tackenberg C; Kulic L; Nitsch RM
PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
[TBL] [Abstract][Full Text] [Related]
18. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
19. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
20. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
